SMARXT
DEAD

Serial Number

98426370

Owner

Immix Biopharma, Inc.

Attorney

Sheila R. Gibson

Filing Date

Feb 28, 2024

Add to watchlist:

No watchlists yet
View on USPTO

SMARXT Trademark

Serial Number: 98426370

SMARXT is a trademark filed by Immix Biopharma, Inc. on February 28, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Immix Biopharma, Inc. (7 trademarks)

10573 W. Pico Blvd #58
Los Angeles, CA 90064

Entity Type: 03

Trademark Details

Filing Date

February 28, 2024

Registration Date

Not Registered

Published for Opposition

October 22, 2024

Goods & Services

anti-cancer preparations; anti-cancer drugs; compounds for treating cancer; pharmaceuticals for the treatment of cancer; pharmaceutical products for the treatment of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical compositions for the treatment of cancer; pharmaceutical drugs for the treatment of cancer; pharmaceutical preparations for human use for the treatment of cancer; pharmaceutical preparations and substances for the treatment of treatment-resistant cancers biological preparations for the treatment of cancer; biological preparations for medical purposes for the treatment of cancer; medical preparations for the treatment of cancer; medicinal preparations and substances for the treatment of cancer; medicines for human purposes for the treatment of cancer; injectable pharmaceuticals for the treatment of cancer; compounds for treating resistant cancers; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for use in chemotherapy; anti-tumor preparations; anti-tumor drugs; tumor suppressing agents; pharmaceutical preparations for suppressing tumors; preparations for treating malignant tumors; medicines for the treatment of gastrointestinal diseases; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for treating gastrointestinal disorders

scientific research in the field of oncology; scientific research in the field of immuo-dysregulated diseases; development of pharmaceutical preparations and medicines for the treatment of cancer; development of pharmaceutical preparations and medicines for the treatment of immuno-dysregulated diseases; clinical research in the field of oncology; clinical research in the field of immuo-dysregulated diseases; research and development services in the field of anti-cancer preparations; research and development services in the field of preparations for treating immuno-dysregulated diseases; design, engineering, research, development and testing services in the field of oncology; design, engineering, research, development and testing services in the field of immuno-dysregulated diseases; providing information regarding medical research relating to oncology; providing information regarding medical research relating to immuno-dysregulated diseases

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Jul 7, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Jul 7, 2025 ABN6
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Dec 3, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 22, 2024 NPUB
PUBLISHED FOR OPPOSITION
Oct 22, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 2, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 17, 2024 CNSA
ASSIGNED TO EXAMINER
Sep 16, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 10, 2024 NWOS
NEW APPLICATION ENTERED
Feb 29, 2024 NWAP